Atypia in Nonneoplastic Prostate Glands After Radiotherapy for Prostate Cancer
- 1 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in The American Journal of Surgical Pathology
- Vol. 27 (2) , 206-212
- https://doi.org/10.1097/00000478-200302000-00009
Abstract
It is unknown how long postradiation atypia of benign prostate glands persists and whether the type of radiation is a factor. Forty-four cases consisting of 37 needle biopsies and 7 transurethral resections of the prostate seen in consultation (January 1997 to September 2000) were studied. In two men (5%), the cases were initially sent without a history of radiotherapy. Thirteen patients had minimal cancer (one core) with the remaining showing no residual tumor. Twenty patients were treated with interstitial radiotherapy (brachytherapy) (IRT), 17 with external beam radiation (XRT), and 7 with a combination of both (CT). The time interval between the treatment and tissue sampling ranged from 8 to 72 months (mean 3 months). Slides were reviewed blindly to the type of radiation and the time interval. Radiation-induced atypia in nonneoplastic glands, stromal fibrosis, and vascular changes was scored separately 0-3, with 0 showing no radiation injury and grade 3 showing prominent nuclear atypia, stromal fibrosis, and vascular hyalinization. We derived a combined score for the epithelial atypia from 0 to 300 (% of glands x grade) for each biopsy. For each case, an overall grade from 0 to 3 was given separately for the stromal and vascular changes. Cases were divided into three groups based on time between treatment and biopsy: 48 months (n = 11). Because the scores for epithelial atypia with IRT and CT were the same, we combined them into one group. There was more atypia in cases treated with IRT/CT (mean score 190) than XRT (mean score 105) (p 48 months after treatment (mean score 57) compared with those with a shorter interval between biopsy and treatment (mean score 132) (p = 0.02). Radiation atypia in benign prostate glands may persist for a long time after the initial treatment, resulting in a significant pitfall in evaluating prostate biopsies. Prominent radiation effect (100% of the glands showing grade 2 and 3 atypia) was detected up to 72 months in one of the patients treated with IRT. In some cases, the clinician may not be aware of a prior remote history of radiation or does not relay this history to the pathologist. The pathologist must recognize radiation atypia without relying on the clinician to provide this history. The type of radiation therapy (IRT/CT vs XRT) is a major factor in the degree and duration of postradiation epithelial atypia.Keywords
This publication has 19 references indexed in Scilit:
- Postradiotherapy prostate biopsies: what do they really mean? results for 498 patientsInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustnessInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Histopathologic Effects of Three-Dimensional Conformal External Beam Radiation Therapy on Benign and Malignant Prostate TissuesThe American Journal of Surgical Pathology, 1999
- Update on the treatment of prostate cancer with external beam irradiationThe Prostate, 1998
- Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinomaCancer, 1997
- Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patientsUrology, 1995
- The significance of post-irradiation prostate biopsy with long-term follow-upInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Carcinoma of the prostate: Results of post‐irradiation biopsyThe Prostate, 1984
- Radiation injury of the normal and neoplastic prostateThe American Journal of Surgical Pathology, 1982
- Significance of prostatic biopsies after radiation therapy for carcinoma of the prostateThe Prostate, 1982